Cidara Reacquires Global Rights to Flu Treatment

 - $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial

- CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment

- Company to host business strategy update conference call and webcast today at 4:30 PM ET

Cidara will host a business strategy update conference call and webcast today, Wednesday, April 24, 2024, at 4:30 PM ET. Details can be found below.

Date:	Wednesday, April 24, 2024
Time:	4:30 PM ET
Conference Call Details:	Toll-free: 1-877-407-4018 International: 1-201-689-8471 Conference ID: 13746332
Call me™ Feature (avoid waiting for operator):	Click Here
Webcast:	Webcast Link – Click Here
https://www.globenewswire.com/news-release/2024/04/24/2869086/0/en/Cidara-Therapeutics-Reacquires-Global-Development-and-Commercial-Rights-to-CD388-and-Announces-Private-Placement-Financing-of-240-Million.html